Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma-Reference-Cited by-同舟云学术

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma

Published:2011-07 Issue:4 Volume:23 Page:373-378
ISSN:1040-8746
Container-title:Current Opinion in Oncology
language:en
Short-container-title:

Author:

Crago Aimee M,Singer Samuel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference21 articles.

1. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk;Dalal;Ann Surg,2006

2. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group;Fletcher;Am J Pathol,1996

3. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis;Meis-Kindblom;Virchows Arch,2001

4. From the archives of the AFIP: imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation;Murphey;Radiographics,2005

5. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group);Rosai;Am J Surg Pathol,1996

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary adrenal sarcomas: A national analysis of epidemiological trends, treatment patterns, and outcomes;Journal of Surgical Oncology;2024-08-27

2. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress;Cell Death Discovery;2024-08-08

3. Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma;Therapeutic Advances in Medical Oncology;2024-01

4. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma;Clinical Cancer Research;2023-09-27

5. Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines;Experimental and Therapeutic Medicine;2023-06-09